What changed today in Metabolic: 4 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
Amylin-based therapies
Amylin analogues and amylin-receptor agonists, such as cagrilintide, studied alone and in combination with GLP-1 therapies for weight management.
Emerging
- Editorial attention
- Emerging
- Tracked this week
- 0
- Sources this week
- 0
- Last activity
- Nov 4, 2026
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Amylin-based therapies at a glance
- About this topic
- Amylin analogues and amylin-receptor agonists, such as cagrilintide, studied alone and in combination with GLP-1 therapies for weight management.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: REDEFINE (A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High…) (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Nov 4, 2026)
- Key facts from tracked records
- 31 clinical trials tracked from ClinicalTrials.gov
- 3 NPHLA briefings on this topic
What’s the latest on Amylin-based therapies?
3 totalWhat changed today in Metabolic: 2 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
What changed today in Metabolic: 7 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records8 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- New trial registered: REDEFINE (A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High…) (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Hypertension; Obesity. Interventions: CagriSema; Semaglutide; Cagrilintide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Trial status changed to “Recruiting”: AMPLIFY-2 (A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Previously “Not yet recruiting”. Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: eloralintide and tirzepatide; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: AMPLIFY-1 (A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Obesity. Interventions: eloralintide and tirzepatide; Eloralintide; Tirzepatide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: AMPLIFY-2 (A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: eloralintide and tirzepatide; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema. Investigational: trial-stage therapies are not approved for the use studied.
- Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial (opens the source in a new tab)
Which clinical trials are being tracked?
All trials- BioM: Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine
Nordlandssykehuset HF. Conditions: Migraine. Status changed from “Not yet recruiting” on Nov 10, 2026. Investigational — not approved for the use studied.
- REDEFINE: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
Novo Nordisk A/S. Conditions: Hypertension; Obesity. Investigational — not approved for the use studied.
- SOLIS-1: A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
Pfizer. Conditions: Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders; Nutritiona…. Investigational — not approved for the use studied.
- ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company. Conditions: Overweight; Obesity. Investigational — not approved for the use studied.
- Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight
Ascletis Pharma (China) Co., Limited. Conditions: Chronic Weight Management. Investigational — not approved for the use studied.